X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$1.01 USD
+0.03 (3.49%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.02 +0.01 (0.99%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
X4 Pharmaceuticals, Inc. [XFOR]
Reports for Purchase
Showing records 61 - 80 ( 92 total )
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New CSO, Art Taveras, Could Help X4 Accelerate Its Preclinical Programs
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Sees a Place For Mavorixafor in Waldenstrom. Reiterating Buy, $23 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Earnings - Waldenstrom Data Expected by YE2020 and SCN Data in 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Update Strengthens Conviction on Mavorixafor for WHIM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor''s EHA Data Boost Confidence in Ongoing Phase 3 Pivotal Study
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor in WHIM - A Match Made at X4. Increasing PT to $23.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Impact from COVID-19 Not Onerous; Adjust PT to $21 from $22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Update - A Strong Cash Position with Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Analyst Day Highlights Market Opportunity for Mavorixafor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
X4 Analyst Day Presentations Suggest Greater Commercial Potential in WHIM
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z